The pharmaceutical industry relies heavily on a complex web of chemical intermediates to synthesize life-saving and health-improving medications. One such compound, 1,4-Dichloro-5,8-dihydroxyanthracene-9,10-dione (CAS 2832-30-6), also known as 5,8-Dichloro-1,4-dihydroxyanthraquinone, plays a vital role as a precursor in various drug synthesis pathways. Understanding its chemical properties and sourcing it reliably is fundamental for pharmaceutical manufacturers.

Chemical Profile and Properties

With a chemical formula of C14H6Cl2O4 and a molecular weight of 309.10 g/mol, this anthraquinone derivative typically appears as a white powder, often supplied with a high purity of 98%. Its molecular structure, featuring hydroxyl and chlorine substitutions on an anthracene core, provides reactive sites that are essential for its function as an intermediate in complex organic synthesis. This makes it a valuable building block for creating advanced pharmaceutical compounds.

Role in Pharmaceutical Synthesis

The significance of 1,4-Dichloro-5,8-dihydroxyanthracene-9,10-dione in the pharmaceutical sector lies in its ability to be transformed into various active pharmaceutical ingredients (APIs) or key components thereof. Its structural backbone can be modified through subsequent chemical reactions to yield molecules with desired therapeutic properties. For pharmaceutical companies, sourcing a consistent and high-quality supply of such intermediates is critical for:

  • Ensuring API Purity: The purity of intermediates directly impacts the purity and efficacy of the final API. Utilizing a 98% pure compound minimizes the risk of unwanted by-products and impurities.
  • Streamlining Synthesis: Having a readily available and well-characterized intermediate simplifies complex multi-step synthesis processes, saving time and resources.
  • Cost-Effective Production: Sourcing from efficient manufacturers, especially those in regions like China, often provides a significant cost advantage for large-scale API production.

Strategic Sourcing for Pharmaceutical Needs

When procuring 1,4-Dichloro-5,8-dihydroxyanthracene-9,10-dione for pharmaceutical applications, manufacturers must focus on:

  • GMP Compliance: While the intermediate itself might not always require full GMP manufacturing, partnering with suppliers who operate under stringent quality management systems is advisable.
  • Documentation and Traceability: Comprehensive documentation, including batch-specific CoAs and adherence to regulatory standards, is crucial for pharmaceutical quality control and regulatory submissions.
  • Supplier Verification: Thoroughly vetting potential suppliers and manufacturers for their track record, capacity, and commitment to quality is essential. Obtaining samples for initial testing is a standard practice.

As the pharmaceutical pipeline continues to demand novel and complex molecules, the role of reliable chemical intermediates like 1,4-Dichloro-5,8-dihydroxyanthracene-9,10-dione will remain indispensable. Pharmaceutical companies looking to purchase CAS 2832-30-6 should prioritize partners who can guarantee quality, consistency, and a secure supply chain.